A Phase 4 interventional study of Dexmedetomidine and Ropivacaine in Postoperative Pain Management, sponsored by Rhode Island Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Rhode Island Hospital · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 24th largest by planned enrollment, is one of 19 that started in 2026, is one of 49 in phase 4, reaches primary completion later than 25 of the 37 other live ones, and was the 116th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–70
Vasiliki Samartzi · Sites in Greece
Ages 20–70 · Women only
Tanta University · Sites in Egypt
Ages 21–60
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Children's Cancer Hospital Egypt 57357 · Sites in Egypt
Ages up to 18
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 23 · Phase 4 49
First in 2008; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 85 across the 136 interventional studies. Of the 70 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 136 have an industry lead sponsor. The 10 most frequent:
Rhode Island Hospital is the lead sponsor of 192 studies on the registry; 37 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Rhode Island Hospital has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
15 of the studies testing dexmedetomidine in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07878156Phase 3Children's Cancer Hospital Egypt 57357Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery. | 2026-12-30 |
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07846722Vasiliki SamartziEsmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery | 2026-12-01 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.
Patients undergoing hip replacement surgery often receive a single-shot suprainguinal fascia iliaca block as a part of the primary anesthetic and multimodal postoperative analgesic strategy. However, the analgesic effect of a single-shot block typically diminishes after several hours and may be inconsistent beyond 24 hours. Adding dexmedetomidine, an alpha-2 agonist, to the local anesthetic has been shown to prolong block duration and reduce postoperative opioid requirements. Investigating its use in suprainguinal fascia iliaca blocks for total hip arthroplasty may clarify its clinical effectiveness. The investigators hypothesize that patients receiving ropivacaine with dexmedetomidine will have a significantly longer time to first analgesic request compared to those receiving ropivacaine alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 ml of 0.25% ropivacaine; No dexmedetomidine
Drug: Ropivacaine
30 ml of 0.25% ropivacaine; 1 mcg/kg of dexmedetomidine
Drug: Dexmedetomidine · Drug: Ropivacaine
Participants in the experimental arm receive a preoperative suprainguinal fascia iliaca block consisting of 30 mL of 0.25% ropivacaine combined with perineural dexmedetomidine at a dose of 1 mcg/kg.
In the experimental arm, ropivacaine (30 mL of 0.25%) is administered with dexmedetomidine. In the active comparator arm, ropivacaine (30 mL of 0.25%) is administered alone without any dexmedetomidine medication.
Time of administration of first analgesic after the surgery
Time frame: Time to first analgesic request, defined as the interval (in minutes) from block administration to the first request for rescue analgesia, assessed for up to 24 hours.
Total opioid consumption (converted to morphine milligram equivalents)
Intraoperative period; PACU; and at 6, 12, 24, and 48 hours following surgery.
Time frame: From the start of surgery through 48 hours postoperatively
Quality of Recovery
The QoR-15 questionnaire has 15 questions that assess patient-reported quality of a patient's postoperative recovery using a 11-point numerical rating scale that leads to a minimum score of 0 (poor recovery) and a maximum score of 150 (excellent recovery).
Time frame: 24 hours
Pain Scores
Patients will be asked to rate their pain score on a 11-point scale (0 = no pain to 10 = excruciating pain).
Time frame: Up to two hours [post anesthesia recovery unit], 6 hours, 12 hours, 24 hours and 48 hours after surgery
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 17 months is close to that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine